

PAXCESS™:

Help patients access PAXLOVID for as little as \$0* for patients with commercial insurance and for free for patients with Medicare, Medicaid, and those who are uninsured†

Pfizer is committed to ensuring that all patients prescribed PAXLOVID have access to PAXLOVID. The PAXCESS Patient Support Program offers:

- ✓ Insurance benefits verification
- ✓ Live PAXCESS representatives who can provide information about insurance benefits and program eligibility
- ✓ Help identifying financial assistance resources

Financial assistance resources include:

Co-Pay Savings Program



If you are commercially insured, pay as little as **\$0*** for your PAXLOVID prescription.

*Eligible commercially insured patients can save up to \$1,500 per prescription. Maximum annual savings up to \$1,500. Full terms and conditions apply to the co-pay program. Please visit www.PAXLOVID.com/paxcess-terms-and-conditions for full terms and conditions.

US Government Patient Assistance Program (USG PAP) operated by Pfizer



For those who don't have commercial insurance, PAXCESS may be able to help with the USG PAP† operated by Pfizer.

†With a focus on ensuring affordable access for patients, the USG Patient Assistance Program operated by Pfizer will continue to provide patients on Medicare, Medicaid, Tricare, VA Community Care Network, and those who are uninsured access to PAXLOVID for free through December 31, 2024. PAXLOVID, through the USG PAP, is not available to patients who have only commercial prescription drug health insurance. The USG PAP operated by Pfizer is an independent program with separate eligibility requirements offered by the United States Department of Health and Human Services and is not owned by Pfizer. Terms and conditions apply. Please see full terms and conditions at PAXLOVID.com/usg-terms-and-conditions.

For more information:



Call toll-free

1-877-C19-PACK
(1-877-219-7225)
Mon-Fri 9 AM-9 PM ET,
Sat-Sun 9 AM-5 PM ET



Text

PAXCESS to 87161
(Co-Pay Savings Program information for patients with commercial insurance only)



Visit

For patients:
PAXLOVID.com/PAXCESS

For providers:
[PAXLOVID.pfizerpro.com/
access-support/access](http://PAXLOVID.pfizerpro.com/access-support/access)



Please see Full Prescribing Information, including BOXED WARNING and Patient Information, here or at PAXLOVID.com.

Paxlovid™
(nirmatrelvir 150 mg tablets | ritonavir 100 mg tablets)

Ensure patients prescribed PAXLOVID know about the PAXCESS™ patient support program

There are many ways to integrate PAXCESS into health system pathways, including:



Electronic Health Records

Develop dot phrases or templated patient instructions for use in **after-visit summaries**. The summary can include links and QR codes.



Pharmacist Dispensing

Implement notifications for pharmacist workflows that can provide a **link to PAXCESS** when patients have a greater than \$0 co-pay.



Post-ordering Provider Workflows

After a provider has made a clinical decision, a notification can be enabled in the workflow that can provide a **link to PAXCESS** when patients have a greater than \$0 co-pay.



Patient Portal

Consider providing a link with the PAXLOVID entry in the medication list. You may also inform providers that they can include links in their **messages** to patients.



Intranet

Make the link a **favorite** in your system intranet for easy access. Your information technology team can also make it available for other providers and staff in your health system.

EHR functionality varies in different systems. Pfizer does not endorse or recommend any specific functionality discussed within the resource and does not assist in building EHR solutions for health systems. This is an educational resource for consideration following a treatment decision.



For assistance with finding the appropriate support program, patients, caregivers, providers, and pharmacists can go to PAXCESSPatientPortal.com.



Please see Full Prescribing Information, including **BOXED WARNING** and Patient Information, [here](#) or at PAXLOVID.com.



© 2024 Pfizer Inc. All rights reserved. PAXCESS, PAXLOVID, and their respective logos are trademarks of Pfizer Inc.
PP-C1D-USA-0285 January 2024

